Charpentier C, Landman R, LaouÃ©nan C, Joly V, Hamet G, Damond F, et al
. Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome. J Antimicrob Chemother. 2012;67:2231-5 pubmed publisher
..LLV seems to be a transient phenomenon that might be driven by residual ongoing viral replication and/or viral release and/or accuracy of viral load assay at lower values. ..
Charpentier C, Lee G, Rodriguez C, Visseaux B, Storto A, Fagard C, et al
. Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response. J Antimicrob Chemother. 2015;70:2090-6 pubmed publisher
..However, these MRVs were not associated with an increased risk of virological failure, except for a trend for etravirine MRVs. ..
Charpentier C, Koyalta D, Ndinaromtan M, Tchobkréo B, Jenabian M, Day N, et al
. Distribution of HIV-1 and HSV-2 epidemics in Chad revealing HSV-2 hot-spot in regions of high-risk HIV spread. J Infect Dev Ctries. 2011;5:64-7 pubmed
..Urgent public health interventions are needed in regions of Chad where high HSV-2 prevalence may be increasing the risk of HIV propagation. ..
Charpentier C, Piketty C, Laureillard D, Tisserand P, Si Mohamed A, Weiss L, et al
. Dynamics of HIV-1 DNA level in highly antiretroviral-experienced patients receiving raltegravir-based therapy. Eur J Clin Microbiol Infect Dis. 2012;31:129-33 pubmed publisher
..The potent action of RAL-containing treatment observed in the CD4 T cells compartment may suggest a pronounced reduced inhibition in the pool of regenerating CD4 T cells on a RAL-based therapy. ..
Charpentier C, Camacho R, Ruelle J, Kaiser R, Eberle J, Gurtler L, et al
. HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe. Clin Infect Dis. 2013;56:1654-8 pubmed publisher
Loubet P, Charpentier C, Visseaux B, Borbor A, Nuta C, Adu E, et al
. Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study. J Antimicrob Chemother. 2015;70:1881-4 pubmed publisher
Charpentier C, Bellecave P, Cisse M, Mamadou S, Diakite M, Peytavin G, et al
. High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger. Antivir Ther. 2011;16:429-33 pubmed publisher
..The prevalence of resistance was between 6% and 9% in both sites, which is higher than most of the other countries from Western Africa region. ..
Charpentier C, Larrouy L, Matheron S, Damond F, Delelis O, Mouscadet J, et al
. Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal. Antivir Ther. 2011;16:937-40 pubmed publisher
Charpentier C, Gody J, Tisserand P, Matta M, Pere H, Fournier J, et al
. Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic. Antivir Ther. 2011;16:1347-50 pubmed publisher
..These observations highlight the need to make an early diagnosis of the possibility of virological failure in Central African children receiving their first-line antiretroviral regimen. ..